Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Double Blind, Placebo-Controlled, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Clinical Trial of AB103, A Peptide Antagonist in Healthy Volunteers.

Next Previous
Trial Profile

Phase 1, Double Blind, Placebo-Controlled, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Clinical Trial of AB103, A Peptide Antagonist in Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reltecimod (Primary)
  • Indications Bacterial infections; Sepsis
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 12 May 2011 Positive tolerability and pharmacokinetic results reported in an Atox Bio media release.
  • 12 May 2011 Status changed from recruiting to completed, as reported in an Atox Bio media release.
  • 15 Sep 2010 Dosing has been completed in the first subject, according to an Atox Bio media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top